Effect of the acute and chronic administration of Lupinus albus β-conglutin on glycaemia, circulating cholesterol, and genes potentially involved.
Animals
Anticholesteremic Agents
/ isolation & purification
Biomarkers
/ blood
Blood Glucose
/ drug effects
Cholesterol
/ blood
Diabetes Mellitus, Experimental
/ blood
Gene Regulatory Networks
Hypoglycemic Agents
/ isolation & purification
Liver
/ drug effects
Lupinus
/ chemistry
Male
Plant Extracts
/ isolation & purification
Plant Proteins
/ isolation & purification
Rats, Wistar
Seed Storage Proteins
/ pharmacology
Streptozocin
Transcriptome
/ drug effects
Anticholesteremic agents
Gene expression profiling
Glucose metabolism
Legumes
Nutraceuticals
Postprandial hyperglycemia
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
07
09
2020
revised:
29
10
2020
accepted:
01
11
2020
pubmed:
10
11
2020
medline:
25
2
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
Constituents of lupin seeds, like γ-conglutin and lupanine, have gained attention as potential complementary treatments for dysglycaemia management. Notwithstanding, the effect of other lupin components on carbohydrate metabolism, including β-conglutin protein, has received little attention. Here, we investigated the influence of the acute and chronic administration of β-conglutin on glycaemia modulation in normal and streptozotocin induced-to-diabetes rats. We analysed the liver transcriptome modulation exerted by β-conglutin in diabetes-induced rats using DNA microarrays to scout for potential molecular targets and pathways involved in this biological response. The acute administration of β-conglutin reduced the incremental area under the curve of glycaemia in normal and diabetes-induced animals. In a seven-day study with diabetic animals, glycaemia increased significantly in non-treated animals but remained unchanged in animals treated with a daily dose of β-conglutin. Total cholesterol was significantly lower at the end of the experimental period (-21.8 %, p = 0.039). The microarray and gene ontology analyses revealed several targets and pathways potentially modulated by β-conglutin treatment, including a possible down-regulation of Jun kinase activity. Moreover, our data indicate that targets related to oxidative stress, inflammation, and estrogenic activity might orchestrate these metabolic effects. In conclusion, our findings show that β-conglutin may help manage postprandial glycaemia and reduce cholesterol levels under the dysglycaemia stage. We identified and proposed new potential molecular targets for further research related to the mechanism of action of β-conglutin.
Identifiants
pubmed: 33166762
pii: S0753-3322(20)31161-6
doi: 10.1016/j.biopha.2020.110969
pii:
doi:
Substances chimiques
Anticholesteremic Agents
0
Biomarkers
0
Blood Glucose
0
Hypoglycemic Agents
0
Plant Extracts
0
Plant Proteins
0
Seed Storage Proteins
0
conglutin protein, Lupinus angustifolius
1391-07-7
Streptozocin
5W494URQ81
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110969Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.